{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1&page=93",
    "query": {
      "intervention": "Part 1",
      "page": 93
    },
    "page_size": 10
  },
  "pagination": {
    "page": 93,
    "page_size": 10,
    "total_count": 6233,
    "total_pages": 624,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1&page=94&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1&page=92&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T19:45:33.235Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01547351",
      "title": "Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "ARMS Questionnaire",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2011-12",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2016-10-19",
      "last_synced_at": "2026-11-14T19:45:33.235Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Oceanside, California • Hollywood, Florida + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01547351"
    },
    {
      "nct_id": "NCT06636786",
      "title": "Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Stress Reaction",
        "Acute Stress Disorder",
        "Neurocognitive Function",
        "Post-traumatic Stress"
      ],
      "interventions": [
        {
          "name": "Cyclobenzaprine HCl",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 180,
      "start_date": "2025-03-25",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-11-14T19:45:33.235Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Indianapolis, Indiana • Kansas City, Kansas + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Camden",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06636786"
    },
    {
      "nct_id": "NCT03275454",
      "title": "A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Purpura, Thrombocytopenic, Idiopathic"
      ],
      "interventions": [
        {
          "name": "BIVV009 6.5 grams",
          "type": "DRUG"
        },
        {
          "name": "BIVV009 7.5 grams",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bioverativ, a Sanofi company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-08-14",
      "completion_date": "2021-02-16",
      "has_results": false,
      "last_update_posted_date": "2023-05-18",
      "last_synced_at": "2026-11-14T19:45:33.235Z",
      "location_count": 3,
      "location_summary": "Georgetown, District of Columbia • Boston, Massachusetts • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Georgetown",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03275454"
    },
    {
      "nct_id": "NCT00584194",
      "title": "Safety and Immunogenicity Study of Rift Valley Fever Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rift Valley Fever"
      ],
      "interventions": [
        {
          "name": "TSI-GSD 200 RVF Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 278,
      "start_date": "2004-06",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2020-01-03",
      "last_synced_at": "2026-11-14T19:45:33.235Z",
      "location_count": 1,
      "location_summary": "Fort Deterick, Maryland",
      "locations": [
        {
          "city": "Fort Deterick",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00584194"
    },
    {
      "nct_id": "NCT03512756",
      "title": "A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "SM-88 used with MPS (methoxsalen, phenytoin, sirolimus)",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine, Gemcitabine, and 5-FU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyme, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2018-03-27",
      "completion_date": "2021-12-28",
      "has_results": true,
      "last_update_posted_date": "2024-11-06",
      "last_synced_at": "2026-11-14T19:45:33.235Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Duarte, California • Santa Monica, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Britain",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03512756"
    },
    {
      "nct_id": "NCT07393373",
      "title": "Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypochondroplasia"
      ],
      "interventions": [
        {
          "name": "Infigratinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QED Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Years to 18 Years"
      },
      "enrollment_count": 135,
      "start_date": "2026-04-23",
      "completion_date": "2036-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-11-14T19:45:33.235Z",
      "location_count": 8,
      "location_summary": "Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07393373"
    },
    {
      "nct_id": "NCT06803745",
      "title": "Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Leukemia",
        "Acute Lymphoblastic Lymphoma"
      ],
      "interventions": [
        {
          "name": "200 cGy or 400 cGy total body irradiation (TBI)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 160,
      "start_date": "2025-03-27",
      "completion_date": "2030-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-11-14T19:45:33.235Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06803745"
    },
    {
      "nct_id": "NCT06595251",
      "title": "Community Park-Based Programs for Health Promotion: Fit2Play Prospective Cohort Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Overweight",
        "Obesity",
        "Hypertension",
        "Prehypertension",
        "Anxiety",
        "Well-being",
        "Depression",
        "Low Physical Fitness",
        "Psychological"
      ],
      "interventions": [
        {
          "name": "Fit2Play curriculum",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "6 Years to 14 Years"
      },
      "enrollment_count": 5000,
      "start_date": "2020-05-07",
      "completion_date": "2027-05-17",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-11-14T19:45:33.235Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06595251"
    },
    {
      "nct_id": "NCT02059031",
      "title": "A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK1265744 Reference formulation",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 New formulation 1",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 New formulation 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-02",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-07-16",
      "last_synced_at": "2026-11-14T19:45:33.235Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02059031"
    },
    {
      "nct_id": "NCT04643002",
      "title": "Isatuximab in Combination With Novel Agents in RRMM - Master Protocol",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Plasma Cell Myeloma Refractory"
      ],
      "interventions": [
        {
          "name": "Isatuximab",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Belantamab mafodotin",
          "type": "DRUG"
        },
        {
          "name": "Pegenzileukin",
          "type": "DRUG"
        },
        {
          "name": "SAR439459",
          "type": "DRUG"
        },
        {
          "name": "Belumosudil",
          "type": "DRUG"
        },
        {
          "name": "Evorpacept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2021-01-25",
      "completion_date": "2028-04-20",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-14T19:45:33.235Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04643002"
    }
  ]
}